tradingkey.logo

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Assembly Modulator in Chronic Hepatitis B

ReutersJun 25, 2025 12:08 PM

- Assembly Biosciences Inc ASMB.O:

  • ASSEMBLY BIOSCIENCES REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1B CLINICAL TRIAL OF NEXT-GENERATION INVESTIGATIONAL CAPSID ASSEMBLY MODULATOR ABI-4334 IN CHRONIC HEPATITIS B

  • ASSEMBLY BIOSCIENCES INC - ABI-4334 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI